Retrophin Inc (NASDAQ:RTRX) SVP William E. Rote sold 1,034 shares of the stock in a transaction that occurred on Wednesday, February 14th. The shares were sold at an average price of $21.50, for a total value of $22,231.00. Following the transaction, the senior vice president now owns 11,156 shares in the company, valued at approximately $239,854. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Retrophin Inc (NASDAQ RTRX) opened at $22.75 on Monday. Retrophin Inc has a twelve month low of $15.55 and a twelve month high of $26.44. The company has a current ratio of 3.88, a quick ratio of 3.83 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $894.23, a P/E ratio of -15.07 and a beta of 1.01.
RTRX has been the topic of several analyst reports. ValuEngine downgraded Retrophin from a “hold” rating to a “sell” rating in a report on Monday, November 20th. Zacks Investment Research downgraded Retrophin from a “hold” rating to a “strong sell” rating in a report on Tuesday, November 14th. Finally, BidaskClub downgraded Retrophin from a “buy” rating to a “hold” rating in a report on Saturday, December 30th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company. Retrophin presently has a consensus rating of “Hold” and a consensus price target of $44.00.
ILLEGAL ACTIVITY WARNING: “William E. Rote Sells 1,034 Shares of Retrophin Inc (RTRX) Stock” was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://stocknewstimes.com/2018/02/19/william-e-rote-sells-1034-shares-of-retrophin-inc-rtrx-stock.html.
Retrophin Company Profile
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.